Peptides / Stack explainer

Wolverine stack (BPC-157 + TB-500)

Editorial still life from the PinPoint compound library series

ILLUSTRATION / COMPOUND LIBRARY SERIES

What is the Wolverine peptide stack?

"Wolverine stack" is a nickname for BPC-157 and TB-500 used together, from two vials or one blended vial. Neither is an FDA-approved drug, and both are banned in sport. FDA found no human data for TB-500. BPC-157 has five small human reports, none using an injection under the skin, so no human dose has been established for either.

At a glance
BPC-157TB-500
What it isSynthetic peptide, 15 amino acids [2]Acetylated 7-amino-acid fragment of thymosin beta-4 (Ac-LKKTETQ) [1]
United StatesNot FDA-approved; FDA reviewers advised against adding it to the 503A bulks list (July 2026) [2]Not FDA-approved; same advice from FDA reviewers [3]
Sport (WADA 2026)Prohibited at all times, S0 [4]Prohibited at all times, S2.3 [4]
Human evidenceFive small studies; a 2026 review rated the evidence "very low" certainty [2][5]None found by FDA [3]

What do the human studies on BPC-157 show?

Very little. FDA's July 2026 review found five human studies.

Two are short conference abstracts on an enema form, and three are small single-clinic reports. FDA's summary: "We found no studies that administered BPC-157 to humans via the proposed oral, SC, nasal, or transdermal ROA" [2]. SC means subcutaneous, under the skin.

A 2026 systematic review of the three published reports (30 people in total) judged all three "to be of poor methodological quality" and rated the overall certainty of evidence "very low" [5].

What the studies used (not a recommendation)

StudyDesignPeopleRouteAmount givenSource
Veljaca et al. 2002 and 2003Placebo-controlled phase 1, meeting abstracts32 healthy adults, 24 given BPC-157Rectal enema0.25, 0.5, 1 or 2 mg/kg, once, then daily for 7 days after a one-week washoutFDA briefing, appendix 1 [2]
Ruenzi et al. 2005Randomized, double-blind, placebo-controlled, meeting abstract53 adults with mild to moderate ulcerative colitis, randomized 1:1Rectal enema80 mg once daily for 2 weeksFDA briefing, appendix 1 [2]
Lee and Padgett 2021Retrospective chart review, one clinic17 adults with knee pain; 16 reached by phone (12 had BPC-157 alone, 4 with thymosin beta-4)Injection into the knee joint2-4 mg, one or two injectionsPubMed 34324435 [6]; amounts from FDA briefing [2]
Lee et al. 2024Single-arm pilot, one clinic12 women with interstitial cystitisInjected into the bladder wall during cystoscopy10 mg total, one procedurePubMed 39325560 [7]
Lee and Burgess 2025Single-arm safety pilot2 healthy adults who had received intravenous BPC-157 beforeIntravenous infusion10 mg on day 1, 20 mg on day 2PubMed 40131143 [8]

None of these amounts was tested under the skin. FDA describes them as doses "that were likely exploratory in nature" [2]. One registered trial of BPC-157 tablets (NCT02637284) planned 42 healthy volunteers and has no posted results [2][9].

Is TB-500 the same as thymosin beta-4?

No, and the difference matters when reading studies. Thymosin beta-4 is a 43-amino-acid protein [3]. TB-500, as analysed in a 2012 anti-doping study, is a seven-amino-acid piece of it with an acetyl group on the end [1]. A 2026 orthopaedic review notes that TB-500 "is frequently conflated with full-length TB-4 despite the absence of validated biologic or clinical equivalence" [14].

A 2010 trial in healthy volunteers tested the full protein, given intravenously [10]. That tells you about thymosin beta-4, not TB-500. FDA's review of TB-500 itself is plain: "The nomination did not include, and FDA has not identified, any clinical studies or human exposure data using TB-500 via any ROA" [3]. ROA means route of administration.

No human dose has been established for TB-500.

One blend vial or two separate vials: what changes?

The arithmetic is the same either way: each peptide's strength is its label milligrams divided by the water. What changes is how much liquid you draw, and whether the two amounts can move on their own.

Arithmetic example, not a dose. The BPC-157 TB-500 blend calculator starts with a label of BPC-157 5 mg and TB-500 10 mg. Mixed with 2 mL, BPC-157 is 2.5 mg/mL and TB-500 is 5 mg/mL. A 10-unit draw (0.1 mL on a U-100 syringe [15]) holds 0.25 mg of BPC-157 and 0.5 mg of TB-500, and the vial holds 20 such draws. Check it in the blend calculator.

Now put the same powder in two vials, 5 mg of BPC-157 and 10 mg of TB-500, each with the same water, mixed the way our reconstitution guide describes. Each vial needs its own 10 units to give the same milligrams, so 20 units of liquid in total instead of 10.

Same label amounts (BPC-157 5 mg, TB-500 10 mg): one blend vial versus two vials
Water per vialBlend: units drawnBlend: BPC-157 / TB-500Two vials: units drawnTwo vials: BPC-157 / TB-500Draws per vial
1 mL100.5 mg / 1 mg10 + 10 = 200.5 mg / 1 mg10
2 mL100.25 mg / 0.5 mg10 + 10 = 200.25 mg / 0.5 mg20
3 mL100.167 mg / 0.333 mg10 + 10 = 200.167 mg / 0.333 mg30

So the blend halves the liquid and locks the ratio. On this label, TB-500 is always twice the BPC-157, and the only way to change one amount is to change both. Two vials take twice the volume but let each number move on its own. For one vial at a time, the BPC-157 calculator and TB-500 calculator do the single-vial version.

Is the Wolverine stack legal, and what are the risks?

Neither peptide is an approved drug in the US, and neither is on FDA's 503A bulks list that lets pharmacies compound with a substance [11]. Both were considered at FDA's Pharmacy Compounding Advisory Committee on 23 July 2026 [13]. In both briefing documents FDA's reviewers wrote that "a balancing of the criteria weighs against" listing them [2][3]. FDA has said it will not decide until the committee's input and its reviews are finished [12].

On 30 October 2026, the HHS Office of the Secretary published notice of a draft enforcement policy for compounding with "certain peptide bulk drug substances" while the 503A bulks list is developed through rulemaking [16]. Under this interim policy, HHS "does not intend to take enforcement action" against state-licensed pharmacies, federal facilities or licensed physicians compounding with a peptide in the policy's Appendix A, and may revisit that if a safety signal or quality problem arises [16]. The notice does not name the peptides; Appendix A is in the policy document on the HHS website. It adds no peptide to the bulks list, is not an approval and "does not establish any rights for any person" [16]. We found no final rule published as of 12 November 2026.

FDA concluded that there is not enough clinical safety information to describe BPC-157's safety, and that the safety risks of TB-500 in people are unknown. For both, it raised concern about immunogenicity: an injected peptide, especially one with impurities or aggregates, may trigger an immune response [2][3].

FDA's adverse-event search also turned up a case that fits this exact stack. A woman using a product labelled for research only, containing BPC-157 and TB-500, developed darkening of her skin and gums that came back when she used it again. FDA wrote that "The AEs were likely due to the drug product considering that the AEs occurred upon rechallenge", and added: "because the product contained two peptides it is not possible to assess a potential relationship between BPC-157 and the reported AEs" [2]. A blend makes that question unanswerable.

For athletes, both are on the WADA Prohibited List at all times [4].

How PinPoint records this

PinPoint lists BPC-157 and TB-500 as two compounds, with no combined entry. A draw from a blend vial goes in as two entries, each with compound, dose, site and pain level, so each peptide keeps its own history. The website's BPC-157 and TB-500 blend calculator works out the milligrams of each. Logging is part of PinPoint Pro.

The status of each compound is the regulators' position given above. The app's modeled levels are an estimate from the half-life value stored for each compound, published where a published value exists and an estimate where none does; they are informative only and not a medical reading. PinPoint never suggests an amount.

Get PinPoint on the App Store

Where do these facts come from?

  1. Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500. Drug Test Anal. 2012. PubMed 22962027. https://pubmed.ncbi.nlm.nih.gov/22962027/
  2. FDA. Briefing document, BPC-157-related bulk drug substances, Pharmacy Compounding Advisory Committee, 23-24 July 2026 (section II.D and appendix 1). https://www.fda.gov/media/193343/download
  3. FDA. Briefing document, TB-500-related bulk drug substances, Pharmacy Compounding Advisory Committee, 23-24 July 2026. https://www.fda.gov/media/193349/download
  4. World Anti-Doping Agency. Prohibited List 2026, sections S0 and S2.3. https://www.wada-ama.org/en/prohibited-list
  5. Poolton JT, et al. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg. 2026. PubMed 42885452. https://pubmed.ncbi.nlm.nih.gov/42885452/
  6. Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021. PubMed 34324435. https://pubmed.ncbi.nlm.nih.gov/34324435/
  7. Lee E, et al. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med. 2024. PubMed 39325560. https://pubmed.ncbi.nlm.nih.gov/39325560/
  8. Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025. PubMed 40131143. https://pubmed.ncbi.nlm.nih.gov/40131143/
  9. ClinicalTrials.gov. NCT02637284. https://clinicaltrials.gov/study/NCT02637284
  10. Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010. PubMed 20536472. https://pubmed.ncbi.nlm.nih.gov/20536472/
  11. FDA. Bulk drug substances used in compounding under section 503A of the FD&C Act (content current as of 14 May 2026). https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
  12. FDA. Briefing document introduction, Pharmacy Compounding Advisory Committee, 23-24 July 2026. https://www.fda.gov/media/193342/download
  13. FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (meeting page and agenda). https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
  14. Tham A, et al. Investigational peptides in orthopaedic practice: evidence, safety, and patient counseling for BPC-157, thymosin beta-4, and TB-500. J Am Acad Orthop Surg. 2026. PubMed 42937313. https://pubmed.ncbi.nlm.nih.gov/42937313/
  15. FDA 510(k) summary K233794, insulin syringe: "U-100 means there are 100 units of insulin in every mL." https://www.accessdata.fda.gov/cdrh_docs/pdf23/K233794.pdf
  16. HHS, Office of the Secretary. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (notice of availability of a draft policy). Federal Register, 30 October 2026, 91 FR 68526, document 2026-22192, docket HHS-OASH-2026-0496. https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances

Updated . Last editorial review by The PinPoint team